首页> 外国专利> Stem cell administration to reduce TNF-α level in CSF of an autism spectrum disorder or pervasive development disorder patient

Stem cell administration to reduce TNF-α level in CSF of an autism spectrum disorder or pervasive development disorder patient

机译:干细胞给药可降低自闭症谱系障碍或广泛性发育障碍患者CSF中的TNF-α水平

摘要

A method for treating an autism spectrum condition includes administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum. A TNF-α inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.
机译:一种治疗自闭症谱系疾病的方法,包括对患有自闭症谱系疾病或弥漫性发育障碍以及脑脊液中TNF-α升高或TNF-α升高中的至少一种的人给予有效剂量的TNF-α抑制剂。与正常情况相比,在血清中;降低脑脊髓液中升高的TNF-α或血清中升高的TNF-α中的至少一种。 TNF-α抑制剂包括来那度胺中的至少一种;和沙利度胺;左旋肌氨酸;英夫利昔单抗;依那西普;干细胞制剂;其衍生物,其异构体或可药用盐。

著录项

  • 公开/公告号US9265755B2

    专利类型

  • 公开/公告日2016-02-23

    原文格式PDF

  • 申请/专利权人 MICHAEL CHEZ;

    申请/专利号US201414261841

  • 发明设计人 MICHAEL CHEZ;

    申请日2014-04-25

  • 分类号A61K38;A61K31/4172;A61K31/454;A61K38/19;A61K31/56;A61K35/28;A61K35/30;A61K36/74;A61K36/9066;C07K14/715;C07K16/24;A61K35/12;

  • 国家 US

  • 入库时间 2022-08-21 14:30:20

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号